Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner
Morie A. Gertz(Medical University of South Carolina), Giampaolo Merlini(University of Pavia), Claudio Rapezzi(University of Ferrara), Philip N. Hawkins(The Royal Free Hospital), Raymond L. Comenzo(Tufts Medical Center), Isabelle Lousada(Amyloidosis Foundation), Sharmila Dorbala(Brigham and Women's Hospital), João Melo Beirão(Universidade do Porto), Marianna Fontana(Amyloidosis Foundation), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Matthew J. Maurer(Mayo Clinic in Arizona), Sabahat Bokhari(Boston University), Arnt V. Kristen(Heidelberg University), Brian Drachman(Penn Presbyterian Medical Center), Thibaud Damy(Amyloidosis Foundation), Martha Grogan(Mayo Clinic in Arizona), Candida Cristina Quarta(Boston University), Ole B. Suhr(Umeå University), José Nativi-Nicolau(Jacksonville College), David Adams(Mount Sinai Health System), Frederick L. Ruberg(Boston University), Teresa Coelho(Universidade do Porto), Ronald Witteles(Alnylam Pharmaceuticals (United States))
Cited by 109
Related Papers
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k